Cocrystal Pharma, Inc., ticker symbol COCP, is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for the treatment of viral diseases. The company is publicly traded and headquartered in Bothell, Washington, United States.
The company was initially formed in 2008 as Biozone Pharmaceuticals, Inc. In January 2014, the name was changed to Cocrystal Pharma, Inc. The change in name reflected the company's new focus on using unique technologies and approaches to create highly effective antiviral therapies.
Cocrystal is known for its unique technologies that are used to create long-acting antiviral therapies for diseases such as hepatitis, influenza, and illnesses caused by coronaviruses. The company's innovative drug discovery platform uses a combination of high-resolution x-ray crystallography, nucleoside chemistry, and computer modeling to create antiviral drug molecules.
Over the years, the company's research efforts have been directed towards several different types of viruses. Cocrystal has developed and licensed a variety of antiviral drug candidates including influenza inhibitors, a non-nucleoside inhibitor for Hepatitis C, and inhibitors for norovirus infections.
One of the notable accomplishments of Cocrystal Pharma includes the development of the drug CC-31244, an experimental treatment for Hepatitis C. This treatment is based on a specific class of drugs known as non-nucleoside inhibitors, which prevent the virus from replicating. The drug has successfully completed Phase 2a clinical trials.
In the context of the COVID-19 pandemic, Cocrystal's focus on antiviral drug discovery and development has become particularly significant. The company has been developing oral antiviral inhibitors for the treatment of Coronavirus infections. It is actively working on two development programs running in parallel to find potential drug candidates to combat COVID-19.
Cocrystal Pharma, Inc. has several collaborations in the biopharmaceutical industry, including a research and development collaboration with Merck Sharp & Dohme Corp. These partnerships enable Cocrystal to combine its proprietary technologies with the expertise of its partners to accelerate the development of antiviral therapeutics.
Despite being a relatively small player in the pharmaceutical industry, Cocrystal Pharma has made significant strides in the areas of antivirals. As the company moves its pipeline forward, it continues to work on the discovery and development of orally-administered, direct-acting broad-spectrum antiviral drugs that are designed to transform the treatment and prevention of viral diseases.